Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jun;113(6):1129-36.
doi: 10.1016/j.jaci.2004.02.006.

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001

David I Bernstein  1 , Mark Wanner, Larry Borish, Gary M Liss; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology
Affiliations

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001

David I Bernstein et al. J Allergy Clin Immunol. 2004 Jun.

Abstract

Background: Fatal reactions associated with skin testing and injection immunotherapy have not been surveyed in North America since 1989.

Objective: A survey of fatal reactions related to skin testing and immunotherapy and of near-fatal immunotherapy reactions that transpired from 1990 through 2001 was conducted among member practices of the American Academy of Allergy, Asthma and Immunology.

Methods: A short survey of fatal reactions was sent to all American Academy of Allergy, Asthma and Immunology physicians, and an 87-item follow-up detailed questionnaire was sent to those reporting fatal reactions.

Results: Of 2404 members, 646 (25%) responded to the short survey. There were 20 fatal immunotherapy reactions that were directly reported and 21 indirectly reported cases by local physicians. There were 273 (42% of the responding sample) reports of near-fatal reactions. It was estimated that fatal reactions occurred every 1 per 2.5 million injections, with an average of 3.4 deaths per year. One fatality was confirmed after skin prick testing with multiple food allergens. Of 17 fatal deaths described in long questionnaires, 15 were in asthmatic patients, the majority of whose symptoms were not optimally controlled. Three reactions occurred in a medically unsupervised setting. None were receiving beta-blockers, and one was taking an angiotensin-converting enzyme inhibitor. Most fatal reactions (59%) occurred with maintenance allergen doses. The onset of 3 reactions began more than 30 minutes after injections, with a significant delay in starting epinephrine. Epinephrine was not administered in 3 other fatal reactors.

Conclusions: Fatal reactions to immunotherapy injections occurred at similar rates reported in previous surveys. Certain clinical practices have improved (ie, exclusion of beta-blockers), and dosing errors were infrequent. Fatal reactions to immunotherapy often occur in settings inappropriate for optimal treatment of anaphylaxis. Strict adherence to practice guidelines might prevent or minimize future fatal reactions.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

  • International consensus on (ICON) pediatric asthma.
    Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, Le Souef P, Mäkelä M, Roberts G, Wong G, Zar H, Akdis CA, Bacharier LB, Baraldi E, van Bever HP, de Blic J, Boner A, Burks W, Casale TB, Castro-Rodriguez JA, Chen YZ, El-Gamal YM, Everard ML, Frischer T, Geller M, Gereda J, Goh DY, Guilbert TW, Hedlin G, Heymann PW, Hong SJ, Hossny EM, Huang JL, Jackson DJ, de Jongste JC, Kalayci O, Aït-Khaled N, Kling S, Kuna P, Lau S, Ledford DK, Lee SI, Liu AH, Lockey RF, Lødrup-Carlsen K, Lötvall J, Morikawa A, Nieto A, Paramesh H, Pawankar R, Pohunek P, Pongracic J, Price D, Robertson C, Rosario N, Rossenwasser LJ, Sly PD, Stein R, Stick S, Szefler S, Taussig LM, Valovirta E, Vichyanond P, Wallace D, Weinberg E, Wennergren G, Wildhaber J, Zeiger RS. Papadopoulos NG, et al. Allergy. 2012 Aug;67(8):976-97. doi: 10.1111/j.1398-9995.2012.02865.x. Epub 2012 Jun 15. Allergy. 2012. PMID: 22702533 Free PMC article.
  • Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study.
    Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Bernstein DI, et al. Ann Allergy Asthma Immunol. 2010 Jun;104(6):530-5. doi: 10.1016/j.anai.2010.04.008. Ann Allergy Asthma Immunol. 2010. PMID: 20568387 Free PMC article. Clinical Trial.
  • Anaphylaxis triggered by prick test with latex extract: a case report.
    Mendonça LO, de Lima CMF, Macedo PRC, Cunha VDES, Hahnstadt RL, Kalil J, Galvão CES. Mendonça LO, et al. Sao Paulo Med J. 2019 May-Jun;137(3):295-297. doi: 10.1590/1516-3180.2017.0295031217. Epub 2018 Jun 11. Sao Paulo Med J. 2019. PMID: 29898012 Free PMC article.
  • Allergen immunotherapy for allergic rhinitis.
    Railey MD, Adair MA, Burks AW. Railey MD, et al. Curr Allergy Asthma Rep. 2008 Mar;8(1):1-3. doi: 10.1007/s11882-008-0001-2. Curr Allergy Asthma Rep. 2008. PMID: 18377767 Review. No abstract available.
  • Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children.
    Tsabouri S, Mavroudi A, Feketea G, Guibas GV. Tsabouri S, et al. Front Pediatr. 2017 Apr 21;5:82. doi: 10.3389/fped.2017.00082. eCollection 2017. Front Pediatr. 2017. PMID: 28484690 Free PMC article. Review.
See all "Cited by" articles

Publication types

LinkOut - more resources